Elicio Therapeutics, Inc.
ELTX
$8.05
$0.091.13%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.29% | -14.47% | -10.58% | -3.14% | 15.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.83% | 43.48% | -3.96% | 40.47% | 31.21% |
| Operating Income | -4.83% | -43.48% | 3.96% | -40.47% | -31.21% |
| Income Before Tax | 5.23% | -56.49% | -76.75% | 4.37% | -47.30% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 5.23% | -56.49% | -76.75% | 4.37% | -47.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.23% | -56.49% | -76.75% | 4.37% | -47.30% |
| EBIT | -4.83% | -43.48% | 3.96% | -40.47% | -31.21% |
| EBITDA | -5.16% | -43.80% | 3.87% | -41.33% | -32.02% |
| EPS Basic | 24.82% | 2.07% | -9.00% | 75.48% | 95.35% |
| Normalized Basic EPS | 24.83% | 3.22% | -10.08% | 77.29% | 95.35% |
| EPS Diluted | 24.82% | 2.07% | -9.00% | 75.48% | 95.35% |
| Normalized Diluted EPS | 24.83% | 3.22% | -10.08% | 77.29% | 95.35% |
| Average Basic Shares Outstanding | 26.05% | 59.79% | 62.15% | 290.05% | 3,069.98% |
| Average Diluted Shares Outstanding | 26.05% | 59.79% | 62.15% | 290.05% | 3,069.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |